Answers are grounded in this paper and cite their sources.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive neoplasm which is typically CD4+, CD56+, and CD123+. There is limited information regarding CD103 expression on blastic plasmacytoid dendritic cell neoplasms. We identified six cases of BPDCN and all six had at least partial CD103 expression (31-92% positive) with the majority having significant expression of CD103.
No takes yet. Share an insight, caveat, or question.
Ron et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: